Mindaugas Jurgutis

Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis

Animesh Pardanani, Claire Harrison, Jörge E. Cortes et al. · JAMA Oncology · 2015 · 453 citations

Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study

Mohamad Mohty, Evangelos Terpos, María‐Victoria Mateos et al. · Clinical Lymphoma Myeloma & Leukemia · 2018 · 89 citations · Full text

Updated results of the placebo‐controlled, phase III JAKARTA trial of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis

Animesh Pardanani, Ayalew Tefferi, Tamás Masszi et al. · British Journal of Haematology · 2021 · 63 citations · Full text

Dose-dense high-dose methylprednisolone and rituximab in the treatment of relapsed or refractory high-risk chronic lymphocytic leukemia

Regina Pileckytė, Mindaugas Jurgutis, Vilma Valčeckienė et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2011 · 33 citations

Results Of a Randomized, Double-Blind, Placebo-Controlled Phase III Study (JAKARTA) Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF)

Animesh Pardanani, Claire Harrison, Jörge E. Cortes et al. · Blood · 2013 · 31 citations